乌鸦传媒

In a highly publicized case, a former Denver cardiologist was found guilty of related to women he met on dating apps, continuing as recently as 2023.

Google announced that is a new feature on the Pixel Watch 3 smartwatch.

Not counting endurance or professional athletes, researchers found that high levels of physical activity were associated with among the general population. (European Heart Journal)

Bristol Myers Squibb has a bone to pick with the newly imposed Maximum Fair Price for , part of the first round of drugs with negotiated prices under the Inflation Reduction Act.

The has been developed to consider a person's platelet phenotype when individualizing antithrombotic therapy. (Nature Communications)

Modulation of circulating ketone levels for patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) is supported by positive data from testing a course of . (Circulation)

In people with HFpEF and excess serum uric acid, add-on did not help exercise capacity and symptoms over allopurinol alone, a randomized trial found. (JAMA Cardiology)

The lipoprotein(a) lowering of olpasiran was in the OCEAN(a)-DOSE trial. (Journal of the American College of Cardiology)

Despite complete endovascular reperfusion, stroke patients can still be left with that are linked to worse functional status at 90 days. (Stroke)

of the donor heart just missed the threshold for significantly improving clinical outcomes for transplant recipients in a randomized trial. (Lancet)

FDA cleared the , an artificial intelligence-powered cardiovascular ultrasound system, Siemens Healthineers said.

For people with , mitral valve surgery was linked to better survival and less heart failure hospitalization compared with medical management alone, observational data suggest. (JAMA Network Open)

Researchers designed a by expanding physically when prompted by a light-emitting catheter, the American Chemical Society (ACS) said.

In other research highlighted by the ACS, scientists are also working on a from a drop of saliva.

Pending a final FDA approval expected in 2025, is tentatively approved for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, Liquidia Corporation said.

Comment